

Stewart Kendrick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2779989/publications.pdf>

Version: 2024-02-01

23
papers

1,331
citations

430754

18
h-index

642610

23
g-index

26
all docs

26
docs citations

26
times ranked

2293
citing authors

#	ARTICLE	IF	CITATIONS
1	Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Medicine, 2019, 17, 95.	2.3	192
2	Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Medicine, 2018, 16, 130.	2.3	177
3	Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ: British Medical Journal, 2019, 367, l5367.	2.4	175
4	Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet, The, 2017, 389, 1114-1123.	6.3	157
5	Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis. Hepatology, 2010, 51, 1988-1997.	3.6	144
6	Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin $\alpha 6 \beta 2$ inhibitor, in healthy participants. European Journal of Clinical Pharmacology, 2018, 74, 701-709.	0.8	52
7	The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility. Hepatology, 2018, 68, 1487-1497.	3.6	48
8	Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom. Clinical Gastroenterology and Hepatology, 2019, 17, 1379-1387.e3.	2.4	43
9	Clinical quantification of the integrin $\alpha 6 \beta 2$ by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study). European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 967-979.	3.3	43
10	Ubiquitin C-terminal hydrolase 1: A novel functional marker for liver myofibroblasts and a therapeutic target in chronic liver disease. Journal of Hepatology, 2015, 63, 1421-1428.	1.8	41
11	Drug treatment of pruritus in liver diseases. Clinical Medicine, 2015, 15, 351-357.	0.8	38
12	Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. Alimentary Pharmacology and Therapeutics, 2018, 48, 951-960.	1.9	34
13	White cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers. BMC Gastroenterology, 2013, 13, 55.	0.8	31
14	Theophylline improves steroid sensitivity in acute alcoholic hepatitis. Hepatology, 2010, 52, 126-131.	3.6	28
15	An "alcohol contract"™ has no significant effect on return to drinking after liver transplantation for alcoholic liver disease. Transplant International, 2014, 27, 475-481.	0.8	27
16	A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis. Frontline Gastroenterology, 2016, 7, 158-166.	0.9	26
17	Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum. Gastroenterology, 2017, 153, 621-625.e7.	0.6	24
18	Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus. Liver International, 2019, 39, 967-975.	1.9	22

#	ARTICLE	IF	CITATIONS
19	Itch and liver: management in primary care. <i>British Journal of General Practice</i> , 2015, 65, e418-e420.	0.7	9
20	Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluations Following Single Oral Doses of GSK2330672 in Healthy Japanese Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 70-77.	0.8	9
21	Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G372-G386.	1.6	5
22	Natural history and factors influencing the course of alcohol-related liver disease. <i>Clinical Liver Disease</i> , 2013, 2, 61-63.	1.0	3
23	Achieving high standards of training. <i>Clinical Medicine</i> , 2009, 9, 514-514.	0.8	1